Skip To Main Content
Dawn Bardot on Muck Rack

Dawn Bardot

As seen in: Taylor & Francis Online, EIN News, EIN Presswire
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Dawn

Contact Dawn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

USPTO Issues Foundational Patent for Leptin Replacement in Anorexia Nervosa, Exclusively Licensed to Zula Therapeutics

|
By Dawn Bardot
| EIN News
Method-of-use patent gives Zula an exclusive position in leptin replacement for anorexia nervosa We are grateful to the patients, institutions, and funders whose support has allowed us to demonstrate the novelty, symptom improvement, and safety of leptin as a treatment for anorexia thus far.” — Professor Johannes Hebebrand, University of Duisburg-Essen, co-inventor BOSTON, MA, UNITED STATES, August 11, 2026 / EINPresswire.com/ -- Zula Therapeutics, Inc.
Open in Who Shared View Duplicates (24) Issue with article?

Use of Bayesian decision analysis to maximize value in patient-centered randomized clinical trials in Parkinson’s disease

|
By Zied Ben Chaouch, Brett Hauber, Stephanie Christopher, Dawn Bardot
| Taylor & Francis Online
6. Discussion In this article, we modify the traditional 5% significance level used in standard RCT designs to better reflect patient preferences and their medical needs. We quantify the loss of value to public health associated with false approvals and rejections, then use BDA to determine the optimal significance level and sample size that minimize this loss, and thereby, maximize this value.
Open in Who Shared Issue with article?
See all 3 articles